Why are antibiotic-resistant nosocomial infections spiraling out of control?

Infection Control and Hospital Epidemiology

Volumn 26, Issue 1, 2005, Pages 10-12

  Muto, Carlene A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; EDITORIAL; HEALTH SURVEY; HOSPITAL INFECTION; INFECTION CONTROL; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRANCE; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 12144259340     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502481     Document Type: Editorial

References (26)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1990-May 1999. Am J Infect Control 1999;27:520-532.
2. Centers for Disease Control and Prevention. NNIS Antimicrobial Resistance Report: Vancomycin-Resistant Enterococcus (VRE) Facts. Atlanta, GA: Centers for Disease Control and Prevention; 1999. Available at www.cdc.gov/phtn/old/ vrefacts.htm.
3. Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance (NNIS) System report: data summary from January 1992-June 2001. Am J Infect Control 2001;29:404-421.
4. Centers for Disease Control and Prevention. Proportion of Healthcare-Acquired S. aureus Infections Resistant to Oxacillin (MRSA) Among ICU Patients, 1989-2003. Atlanta, GA: Centers for Disease Control and Prevention; 2004. Available at www.cdc.gov/ncidod/hip/ARESIST/mrsa.htm.
5. Centers for Disease Control and Prevention. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings: Why a Campaign? Atlanta, GA: Centers for Disease Control and Prevention; 2001. Available at www.cdc.gov/drugresistance/healthcare/problem.htm.
6. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59.
7. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay and hospital charge. Presented at the 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22-25, 2001; Chicago, IL. Abstract K-1221:415.
8. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
9. Salgado CD, Farr BM. Outcomes associated with vancomycin resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690-698.
10. L'Hériteau F, Alberti C, Cohen Y, Troché G, Moine P, Timsit J-F. Nosocomial infection and multidrug-resistant bacteria surveillance in intensive care units: a survey in France. Infect Control Hosp Epidemiol 2005;26:13-20.
11. Ward MM, Diekema DJ, Yankey JW, et al. Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals. Infect Control Hosp Epidemiol 2005;26:21-30.
12. Flach SD, Diekema DJ, Yankey JW, et al. Variation in the use of procedures to monitor antimicrobial resistance in U.S. hospitals. Infect Control Hosp Epidemiol 2005:26:31-38.
13. Lee TA, Hacek DM, Stroupe KT, Collins SM, Peterson LR. Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients: detection of colonization efficiency and a cost-effectiveness model. Infect Control Hosp Epidemiol 2005;26:39-46
14. Bolon MK, Arnold AD, Feldman HA, et al. Evaluating vancomycin use at a pediatric hospital: new approaches and insights. Infect Control Hosp Epidemiol 2005;26:47-55.
15. Comité Technique National des Infections Nosocomiales. 100 Recommendations for Surveillance and Prevention of Nosocomial Infections. Paris: Ministere de l'Emploi et de la Solidarité; 1999.
16. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996;275:234-240.
17. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386.
18. Calfee DP, Giannetta ET, Durbin LJ, Farr BM. Control of endemic vancomycin-resistant Enterococcus (VRE) among inpatients at a university hospital. Clin Infect Dis 2003;37:326-332.
19. Salgado CD, Farr BM. What proportion of hospital patients colonized with methicillin-resistant Staphylococcus aureus are identified by clinical microbiology cultures? Presented at the 13th Annual Meeting of the Society for Healthcare Epidemiology of America; April 5-8, 2003; Arlington, VA.
20. Vriens MR, Fluit AC, Troelstra A, Verhoef J, Van Der Werken C. Are MRSA more contagious than MSSA in a surgical intensive care unit? Infect Control Hosp Epidemiol 2002;23:491-494.
21. Jernigan JA, Titus MG, Groschel DHM, Getchell-White SI, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996;143:496-504.
22. HICPAC. Recommendations for preventing the spread of vancomycin resistance: Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;16:105-113.
23. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999;159:2461-2468.
24. Centers for Disease Control and Prevention. Public Health Guidance for Community-Level Preparedness and Response to SARS Atlanta, GA: Centers for Disease Control and Prevention; 2004. Available at www.cdc.gov/ncidod/sars/ guidance/index.htm.
25. Centers for Disease Control and Prevention. Health Department and Infection Control Guidance: Investigation and Control of Vancomycin Intermediate and Resistant Staphylococcus aureus (VISA/VRSA). Atlanta, GA: Centers for Disease Control and Prevention; 2004. Available at www.cdc.gov/ncidod/hip/ ARESIST/visa_vrsa_guide.pdf.
26. Centers for Disease Control and Prevention. Draft guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings, 2004. Federal Register 2004;69:33034.